Jefferies Financial Group Inc. Acquires Shares of 580,328 SAB Biotherapeutics, Inc. $SABS

Jefferies Financial Group Inc. acquired a new stake in SAB Biotherapeutics, Inc. (NASDAQ:SABS) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 580,328 shares of the company’s stock, valued at approximately $2,170,000. Jefferies Financial Group Inc. owned about 1.22% of SAB Biotherapeutics at the end of the most recent reporting period.

Several other large investors have also made changes to their positions in the business. ADAR1 Capital Management LLC purchased a new stake in shares of SAB Biotherapeutics in the 3rd quarter valued at $30,000. Dimensional Fund Advisors LP purchased a new stake in shares of SAB Biotherapeutics in the 3rd quarter valued at $32,000. Virtu Financial LLC purchased a new stake in shares of SAB Biotherapeutics in the 3rd quarter valued at $40,000. Woodline Partners LP purchased a new stake in shares of SAB Biotherapeutics in the 3rd quarter valued at $5,730,000. Finally, Commodore Capital LP purchased a new stake in shares of SAB Biotherapeutics in the 3rd quarter valued at $8,847,000. 7.82% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several analysts have recently commented on SABS shares. Zacks Research raised shares of SAB Biotherapeutics from a “strong sell” rating to a “hold” rating in a report on Monday, May 11th. Chardan Capital upped their price objective on shares of SAB Biotherapeutics from $12.00 to $14.00 and gave the company a “buy” rating in a report on Wednesday, March 11th. HC Wainwright upped their price objective on shares of SAB Biotherapeutics from $7.00 to $10.00 and gave the company a “buy” rating in a report on Tuesday, May 12th. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of SAB Biotherapeutics in a report on Friday, April 10th. Finally, Jefferies Financial Group initiated coverage on shares of SAB Biotherapeutics in a report on Wednesday, May 20th. They issued a “buy” rating and a $11.00 price objective on the stock. One research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $11.00.

SAB Biotherapeutics Stock Performance

SABS opened at $3.81 on Wednesday. The company has a debt-to-equity ratio of 0.01, a current ratio of 11.45 and a quick ratio of 11.45. The firm has a fifty day moving average price of $3.81 and a 200 day moving average price of $3.86. SAB Biotherapeutics, Inc. has a 1 year low of $1.60 and a 1 year high of $6.60. The stock has a market cap of $291.31 million, a P/E ratio of -1.81 and a beta of 0.55.

SAB Biotherapeutics (NASDAQ:SABS) last posted its earnings results on Tuesday, May 12th. The company reported ($0.35) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.20) by ($0.15). Equities research analysts anticipate that SAB Biotherapeutics, Inc. will post -1.19 earnings per share for the current year.

SAB Biotherapeutics Profile

SAB Biotherapeutics, Inc is a clinical-stage biotechnology company headquartered in Sioux Falls, South Dakota, that focuses on developing fully human polyclonal antibody therapeutics. The company’s proprietary platform, known as Tc Bovine®, uses genetically engineered cattle to generate large quantities of human antibodies tailored to target specific infectious agents or disease-related antigens. This approach is designed to combine the broad-spectrum coverage of polyclonal antibody therapies with the scalability and consistency required for clinical development and commercial use.

The company’s lead programs are directed primarily at infectious diseases.